

RECEIVED

MAR 26 2002

OFFICE OF PETITIONS

RECEIVED

MAR 22 2002

TECH CENTER 1600/2900

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/017,735A

DATE: 03/11/2002

TIME: 09:57:51

Input Set : D:\39963-20008.txt
 Output Set: N:\CRF3\03112002\I017735A.raw



ENTERED

1600

RECEIVED

MAR 22 2002

OFFICE OF PETITIONS

4 <110> APPLICANT: EPIMMUNE, Inc.
 5 Grey, Howard
 6 Sette, Alessandro
 7 Sidney, John
 8 Southwood, Scott
 10 <120> TITLE OF INVENTION: HLA-A2.1 BINDING PEPTIDES AND THEIR USES
 13 <130> FILE REFERENCE: 39963-20008.20
 15 <140> CURRENT APPLICATION NUMBER: US 09/017,735A
 16 <141> CURRENT FILING DATE: 1998-02-03
 18 <160> NUMBER OF SEQ ID NOS: 195
 20 <170> SOFTWARE: FastSEQ for Windows Version 4.0
 22 <210> SEQ ID NO: 1
 23 <211> LENGTH: 9
 24 <212> TYPE: PRT
 25 <213> ORGANISM: Artificial Sequence
 27 <220> FEATURE:
 28 <223> OTHER INFORMATION: Immunogenic peptide from TSA-1 641
 30 <400> SEQUENCE: 1
 31 Phe Leu Tyr Asn Arg Pro Leu Ser Val
 32 1 5
 34 <210> SEQ ID NO: 2
 35 <211> LENGTH: 9
 36 <212> TYPE: PRT
 37 <213> ORGANISM: Artificial Sequence
 39 <220> FEATURE:
 40 <223> OTHER INFORMATION: Immunogenic peptide from TSA-1 818
 42 <400> SEQUENCE: 2
 43 Val Leu Leu Pro Ser Leu Phe Leu Leu
 44 1 5
 46 <210> SEQ ID NO: 3
 47 <211> LENGTH: 9
 48 <212> TYPE: PRT
 49 <213> ORGANISM: Artificial Sequence
 51 <220> FEATURE:
 52 <223> OTHER INFORMATION: Immunogenic peptide from TSA-1 819
 54 <400> SEQUENCE: 3
 55 Leu Leu Pro Ser Leu Phe Leu Leu Leu
 56 1 5
 58 <210> SEQ ID NO: 4
 59 <211> LENGTH: 9
 60 <212> TYPE: PRT
 61 <213> ORGANISM: Artificial Sequence
 63 <220> FEATURE:

RAW SEQUENCE LISTING

DATE: 03/11/2002

PATENT APPLICATION: US/09/017,735A

TIME: 09:57:51

Input Set : D:\39963-20008.txt

Output Set: N:\CRF3\03112002\I017735A.raw

64 <223> OTHER INFORMATION: Immunogenic peptide from TSA-1 514
 66 <400> SEQUENCE: 4
 67 Phe Val Asp Tyr Asn Phe Thr Ile Val
 68 1 5
 70 <210> SEQ ID NO: 5
 71 <211> LENGTH: 9
 72 <212> TYPE: PRT
 73 <213> ORGANISM: Artificial Sequence
 75 <220> FEATURE:
 76 <223> OTHER INFORMATION: Immunogenic peptide from TSA-1 89
 78 <400> SEQUENCE: 5
 79 Lys Leu Phe Pro Glu Val Ile Asp Leu
 80 1 5
 82 <210> SEQ ID NO: 6
 83 <211> LENGTH: 10
 84 <212> TYPE: PRT
 85 <213> ORGANISM: Artificial Sequence
 87 <220> FEATURE:
 88 <223> OTHER INFORMATION: Immunogenic peptide from TSA-1 824
 90 <400> SEQUENCE: 6
 91 Phe Leu Leu Leu Gly Leu Trp Gly Phe Ala
 92 1 5 10
 94 <210> SEQ ID NO: 7
 95 <211> LENGTH: 10
 96 <212> TYPE: PRT
 97 <213> ORGANISM: Artificial Sequence
 99 <220> FEATURE:
 100 <223> OTHER INFORMATION: Immunogenic peptide from TSA-1 818
 102 <400> SEQUENCE: 7
 103 Val Leu Leu Pro Ser Leu Phe Leu Leu Leu
 104 1 5 10
 106 <210> SEQ ID NO: 8
 107 <211> LENGTH: 10
 108 <212> TYPE: PRT
 109 <213> ORGANISM: Artificial Sequence
 111 <220> FEATURE:
 112 <223> OTHER INFORMATION: Immunogenic peptide from TSA-1 398
 114 <400> SEQUENCE: 8
 115 Leu Leu Tyr Ser Asp Asp Ala Leu His Leu
 116 1 5 10
 118 <210> SEQ ID NO: 9
 119 <211> LENGTH: 9
 120 <212> TYPE: PRT
 121 <213> ORGANISM: Artificial Sequence
 123 <220> FEATURE:
 124 <223> OTHER INFORMATION: Immunogenic peptide from MT 32k 178
 126 <400> SEQUENCE: 9
 127 Ala Ile Tyr His Pro Gln Gln Phe Val
 128 1 5

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/017,735A

DATE: 03/11/2002

TIME: 09:57:51

Input Set : D:\39963-20008.txt

Output Set: N:\CRF3\03112002\I017735A.raw

130 <210> SEQ ID NO: 10
131 <211> LENGTH: 9
132 <212> TYPE: PRT
133 <213> ORGANISM: Artificial Sequence
135 <220> FEATURE:
136 <223> OTHER INFORMATION: Immunogenic peptide from MT 85c 317
138 <400> SEQUENCE: 10
139 Ala Met Lys Ala Asp Ile Gln His Val
140 1 5
142 <210> SEQ ID NO: 11
143 <211> LENGTH: 9
144 <212> TYPE: PRT
145 <213> ORGANISM: Artificial Sequence
147 <220> FEATURE:
148 <223> OTHER INFORMATION: Immunogenic peptide from MT 65k 285
150 <400> SEQUENCE: 11
151 Ala Met Leu Gln Asp Met Ala Ile Leu
152 1 5
154 <210> SEQ ID NO: 12
155 <211> LENGTH: 9
156 <212> TYPE: PRT
157 <213> ORGANISM: Artificial Sequence
159 <220> FEATURE:
160 <223> OTHER INFORMATION: Immunogenic peptide from MT superoxide dismutase
161 160
163 <400> SEQUENCE: 12
164 Asp Met Trp Glu His Ala Phe Tyr Leu
165 1 5
167 <210> SEQ ID NO: 13
168 <211> LENGTH: 9
169 <212> TYPE: PRT
170 <213> ORGANISM: Artificial Sequence
172 <220> FEATURE:
173 <223> OTHER INFORMATION: Immunogenic peptide from MT 65k 509
175 <400> SEQUENCE: 13
176 Gly Leu Phe Leu Thr Thr Glu Ala Val
177 1 5
179 <210> SEQ ID NO: 14
180 <211> LENGTH: 9
181 <212> TYPE: PRT
182 <213> ORGANISM: Artificial Sequence
184 <220> FEATURE:
185 <223> OTHER INFORMATION: Immunogenic peptide from MT alanine dehydrogenase
186 92
188 <400> SEQUENCE: 14
189 Ile Leu Phe Thr Phe Leu His Leu Ala
190 1 5
192 <210> SEQ ID NO: 15
193 <211> LENGTH: 9

RAW SEQUENCE LISTING

DATE: 03/11/2002

PATENT APPLICATION: US/09/017,735A

TIME: 09:57:51

Input Set : D:\39963-20008.txt

Output Set: N:\CRF3\03112002\I017735A.raw

194 <212> TYPE: PRT
195 <213> ORGANISM: Artificial Sequence
197 <220> FEATURE:
198 <223> OTHER INFORMATION: Immunogenic peptide from MT 65k 369
200 <400> SEQUENCE: 15
201 Lys Leu Ala Gly Gly Val Ala Val Ile
202 1 5
204 <210> SEQ ID NO: 16
205 <211> LENGTH: 9
206 <212> TYPE: PRT
207 <213> ORGANISM: Artificial Sequence
209 <220> FEATURE:
210 <223> OTHER INFORMATION: Immunogenic peptide from MT 85B 15
212 <400> SEQUENCE: 16
213 Leu Met Ile Gly Thr Ala Ala Ala Val
214 1 5
216 <210> SEQ ID NO: 17
217 <211> LENGTH: 9
218 <212> TYPE: PRT
219 <213> ORGANISM: Artificial Sequence
221 <220> FEATURE:
222 <223> OTHER INFORMATION: Immunogenic peptide from MT 65k 286
224 <400> SEQUENCE: 17
225 Met Leu Gln Asp Met Ala Ile Leu Thr
226 1 5
228 <210> SEQ ID NO: 18
229 <211> LENGTH: 9
230 <212> TYPE: PRT
231 <213> ORGANISM: Artificial Sequence
233 <220> FEATURE:
234 <223> OTHER INFORMATION: Immunogenic peptide from MT 85B 14
236 <400> SEQUENCE: 18
237 Arg Leu Met Ile Gly Thr Ala Ala Ala
238 1 5
240 <210> SEQ ID NO: 19
241 <211> LENGTH: 9
242 <212> TYPE: PRT
243 <213> ORGANISM: Artificial Sequence
245 <220> FEATURE:
246 <223> OTHER INFORMATION: Immunogenic peptide from MT 32k 178
248 Immunogenic peptide from MT 32k 25
250 <400> SEQUENCE: 19
251 Arg Leu Val Ser Gly Leu Val Gly Ala
252 1 5
254 <210> SEQ ID NO: 20
255 <211> LENGTH: 9
256 <212> TYPE: PRT
257 <213> ORGANISM: Artificial Sequence
259 <220> FEATURE:

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/017,735A

DATE: 03/11/2002

TIME: 09:57:52

Input Set : D:\39963-20008.txt

Output Set: N:\CRF3\03112002\I017735A.raw

260 <223> OTHER INFORMATION: Immunogenic peptide from MT 70k 318
 262 <400> SEQUENCE: 20
 263 Arg Met Pro Ala Val Thr Asp Leu Val
 264 1 5
 266 <210> SEQ ID NO: 21
 267 <211> LENGTH: 9
 268 <212> TYPE: PRT
 269 <213> ORGANISM: Artificial Sequence
 271 <220> FEATURE:
 272 <223> OTHER INFORMATION: Immunogenic peptide from MT 70k 179
 274 <400> SEQUENCE: 21
 275 Ser Leu Leu Glu Ile Gly Glu Gly Val
 276 1 5
 278 <210> SEQ ID NO: 22
 279 <211> LENGTH: 9
 280 <212> TYPE: PRT
 281 <213> ORGANISM: Artificial Sequence
 283 <220> FEATURE:
 284 <223> OTHER INFORMATION: Immunogenic peptide from MT 70k 363
 286 <400> SEQUENCE: 22
 287 Val Leu Leu Leu Asp Val Thr Pro Leu
 288 1 5
 290 <210> SEQ ID NO: 23
 291 <211> LENGTH: 9
 292 <212> TYPE: PRT
 293 <213> ORGANISM: Artificial Sequence
 295 <220> FEATURE:
 296 <223> OTHER INFORMATION: Immunogenic peptide from MT 85c 137
 298 <400> SEQUENCE: 23
 299 Tyr Thr Tyr Lys Trp Glu Thr Phe Leu
 300 1 5
 302 <210> SEQ ID NO: 24
 303 <211> LENGTH: 9
 304 <212> TYPE: PRT
 305 <213> ORGANISM: Artificial Sequence
 307 <220> FEATURE:
 308 <223> OTHER INFORMATION: Immunogenic peptide from Lassa gp 343
 310 <400> SEQUENCE: 24
 311 Ala Leu Ile Asn Asp Gln Leu Ile Met
 312 1 5
 314 <210> SEQ ID NO: 25
 315 <211> LENGTH: 9
 316 <212> TYPE: PRT
 317 <213> ORGANISM: Artificial Sequence
 319 <220> FEATURE:
 320 <223> OTHER INFORMATION: Immunogenic peptide from Lassa Josiah(NP) 376
 322 <400> SEQUENCE: 25
 323 Ala Met Leu Gln Leu Asp Pro Asn Ala
 324 1 5

→ Use of n and / or Xaa has been detected in the Sequence Listing. Review the Sequence Listing to ensure a corresponding explanation is present in the <220> to <223> fields of each sequence using n or Xaa.

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/017,735A

DATE: 03/11/2002

TIME: 09:57:53

Input Set : D:\39963-20008.txt

Output Set: N:\CRF3\03112002\I017735A.raw

L:2475 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:2484 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:2492 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:192
L:2507 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:2516 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:2519 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:193
L:2534 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:2545 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:194
L:2560 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:2570 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:195